Heart Failure

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

The investigative therapy from Windtree Therapeutics also maintained a favorable safety and tolerability profile versus placebo.

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.

Recent analyses detail the ongoing risk of hyperkalemia in heart failure patients, highlighting the importance of optimal medication dosing.

An analysis of data from the HELIOS-B trial indicated an overall reduction in GI events among the vutrisiran cohort compared to those receiving placebo.

100% of included participants were successfully defibrillated and exhibited 6-month improvements or stability in the majority of patients.

Guideline-directed medical therapy and SGLT2i use has been associated with reduced total health care costs and a lower risk of hospitalization and death.

If this connection is proven, the gut microbiome may present an entirely new pathway for treatment and prevention of heart failure.

Patients taking multiple drugs simultaneously receive the same protective effect from finerenone, regardless of their degree of polypharmacy.

New research links marijuana use to higher readmission and mortality rates in heart failure patients.

Recent studies reveal finerenone's superior benefits over traditional MRAs in heart failure, showing reduced mortality and hospitalization rates.

A recent publication from the HFSA highlights obesity, chronic kidney disease, diabetes mellitus, and hypertension as major driving forces.

A compiled list of the 8 most exciting presentations scheduled for the Heart Failure Society of American Annual Scientific Meeting 2025.

In a study, the prevalence of transthyretin cardiac amyloidosis reached 17% in Black men over 75 years old.

AKINESIS study finds kidney tubule biomarker IGFBP‑7 predicts 1-year death and heart failure readmission in acute heart failure patients.

Parent company CeleCor Therapeutics announced positive safety and efficacy endpoint data for their investigative GPIIb/IIIa inhibitor versus placebo.

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

When compared to transitions of care coordinators, MIH saw no additional benefit to either health status or 30-day hospital readmissions for postacute patients with HF.

The US Food and Drug Administration has approved bumetanide nasal spray for the treatment of edema in outpatient heart, liver, and kidney diseases.

Compared to standard devices, the first-of-its-kind AIRE-CHB model indicated incident CHB risk, outperforming standard ECG devices.

Life’s Essential 8 scores are substantially lower among adults aged ≥65 years who exhibit high blood pressure, stroke, or other cardiovascular diseases.

In the final segment of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 6 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.